House Concurrent Resolution No. 17

99TH GENERAL ASSEMBLY

INTRODUCED BY REPRESENTATIVE HUBRECHT.

1539H.01I

	WHEREAS, meningococcal disease is any infection caused by the bacterium Neisseria
2	meningitidis, or meningococcus. Although 1 in 10 people are carriers for this bacteria with no
3	signs or symptoms of disease, sometimes Neisseria meningitidis bacteria can cause illness; and
4	
5	WHEREAS, meningococcal disease is spread from person to person via the exchange
6	of the bacteria through respiratory and throat secretion during close or lengthy contact; and
7	
8	WHEREAS, in the U.S. there are approximately 1,000 to 1,200 cases of meningococcal
9	disease that occur each year; and
10	
11	WHEREAS, 10 to 15 percent of infected individuals will die, while 11 to 19 percent of
12	those who live will suffer from serious morbidity, including loss of limbs and impacts to the
13	nervous system; and
14	
15	WHEREAS, infants under one year of age as well as young adults between the ages of
16	16 and 21 are most commonly impacted by this disease; and
17	
18	WHEREAS, there are different strains or serogroups of Neisseria meningitidis, with
19	serogroups B, C, and Y accounting for most meningococcal diseases in the U.S.; and
20	
21	WHEREAS, there have been several recent outbreaks of serogroup B meningococcal
22	disease on college campuses, with some cases resulting in death; and
23	
24	WHEREAS, vaccines are available to prevent meningococcal disease, and different
25	vaccines provide coverage against certain specific serogroups of the disease; and
26	
27	WHEREAS, while there are vaccines that help provide protection against all three
28	serogroups (B, C, and Y) commonly seen in the U.S., only vaccination for serogroups A, C, W,
29	and Y is routinely recommended by the Centers for Disease Control and Prevention; and
30	

HCR 17

WHEREAS, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommends that decisions to vaccinate adolescents and young adults 16 through 23 years of age against serogroup B meningococcal disease should be made at the individual level with health care providers; and

35

WHEREAS, it is critical that students, parents, educators, and health care providers understand the dangers of meningitis B and are aware that a vaccine is available to prevent disease resulting from this serogroup:

39

40 NOW THEREFORE BE IT RESOLVED that the members of the House of 41 Representatives of the Ninety-ninth General Assembly, First Regular Session, the Senate 42 concurring therein, hereby find that the recent incidence of meningococcal disease has served 43 as a reminder of the critical role vaccinations play in helping to prevent this devastating illness; 44 and

45

BE IT FURTHER RESOLVED that the Department of Health and Senior Services take
all reasonable steps to urge all private and public high schools, colleges, and universities in
Missouri to provide information to all students and parents about meningococcal disease,
explaining the different disease serogroups, symptoms, risks, and treatment; and

50

51 **BE IT FURTHER RESOLVED** that such information shall also include a notice of 52 availability, benefits, risks, and limitations of all meningococcal vaccines receiving a 53 recommendation from the Advisory Committee on Immunization Practices, including Category 54 A and Category B recommendations, with specific information as to those persons at higher risk 55 for the disease; and

56

57 **BE IT FURTHER RESOLVED** that each private and public high school, college, and 58 university shall recommend that current and entering students receive meningococcal vaccines 59 in accordance with current Advisory Committee on Immunization Practices guidelines; and 60

61 **BE IT FURTHER RESOLVED** that the Chief Clerk of the Missouri House of 62 Representatives be instructed to prepare a properly inscribed copy of this resolution for every 63 private and public high school, college, and university in Missouri.